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Abstract
Summary This paper reviews the evidence for an associa-
tion between atypical subtrochanteric fractures and long-
term bisphosphonate use. Clinical case reports/reviews and
case–control studies report this association, but retrospec-
tive phase III trial analyses show no increased risk.
Bisphosphonate use may be associated with atypical
subtrochanteric fractures, but the case is yet unproven.
Introduction A Working Group of the European Society on
Clinical and Economic Aspects of Osteoporosis and
Osteoarthritis and the International Osteoporosis Founda-
tion has reviewed the evidence for a causal association
between subtrochanteric fractures and long-term treat-
ment with bisphosphonates, with the aim of identifying
areas for further research and providing recommendations
for physicians.
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DOI 10.1007/s00198-010-1453-5Methods A PubMed search of literature from 1994 to May
2010 was performed using key search terms, and articles
pertinent to subtrochanteric fractures following bisphosph-
onate use were analysed.
Results Several clinical case reports and case reviews report
a possible association between atypical fractures at the
subtrochanteric region of the femur in bisphosphonate-
treated patients. Common features of these ‘atypical’
fractures include prodromal pain, occurrence with mini-
mal/no trauma, a thickened diaphyseal cortex and trans-
verse fracture pattern. Some small case–control studies
report the same association, but a large register-based study
and retrospective analyses of phase III trials of bisphosph-
onates do not show an increased risk of subtrochanteric
fractures with bisphosphonate use. The number of atypical
subtrochanteric fractures in association with bisphospho-
nates is an estimated one per 1,000 per year. It is
recommended that physicians remain vigilant in assessing
their patients treated with bisphosphonates for the treatment
or prevention of osteoporosis and advise patients of the
potential risks.
Conclusions Bisphosphonate use may be associated with
atypical subtrochanteric fractures, but the case is unproven
and requires further research. Were the case to be proven,
the risk–benefit ratio still remains favourable for use of
bisphosphonates to prevent fractures.
Keywords Atypical.Bisphosphonate.Femur.Low
trauma.Osteoporosis.Subtrochanteric
Introduction
Treatment with bisphosphonates significantly reduces the
risk of fractures in men and women with osteoporosis. The
evidence is based on high-quality phase III randomized
controlled trials (RCTs) with fracture as an endpoint [1–10].
The benefits of bisphosphonates also extend to other
disorders of bone metabolism such as glucocorticoid-
induced osteoporosis [11], Paget’s disease [12] and bone
metastases [13, 14].
Treatment with bisphosphonates is not without adverse
effects, but they are generally minor and occur in a minority
of patients. The most common adverse effect is gastroin-
testinal upset with the oral formulations, the frequency of
which decreases with intermittent treatment such as once-
weekly or monthly regimens. Intravenous (IV) administra-
tion of nitrogen-containing bisphosphonates may induce an
acute phase reaction which manifests as fever, myalgia and
arthralgia, although these side effects usually resolve within
a few days of onset [3, 7, 15]. High doses of bisphosph-
onates given intravenously may impair renal function, and
the kidney is a major route of elimination of the
bisphosphonates. For this reason, bisphosphonates are not
recommended for use in patients with severe renal
impairment [16–18]. The use of bisphosphonates has been
associated with osteonecrosis of the jaw, but most cases
have occurred in patients receiving high-dose IV
bisphosphonates for neoplastic bone disease, and osteonec-
rosis of the jaw has rarely been reported in patients with
benign bone diseases [19, 20]. An increased risk of atrial
fibrillation has been reported for zoledronic acid [3], but the
association may be coincidental [7]. Other uncommon or
rare side effects of bisphosphonates include anaemia [21],
urticaria [22, 23] and symptomatic hypocalcaemia [22].
In recent years, several clinical case reports and case
reviews have reported an association between atypical
fractures in patients receiving treatment with bisphospho-
nates. The majority of these cases have described fractures
at the subtrochanteric region of the femur [24–31].
Against this background, the aim of this report was to
critically review the evidence for an increased incidence of
subtrochanteric fractures after long-term treatment with
bisphosphonates, to identify gaps in our knowledge that
warrant further research and to provide guidance for
healthcare professionals. A PubMed search of literature
from 1994 to May 2010 was performed using the search
terms ‘bisphosphonate(s)’ AND/OR ‘alendronate’ AND/
OR ‘risedronate’ AND/OR ‘ibandronate/ibandronic acid’
AND/OR ‘zoledronate/zoledronic acid’ AND/OR ‘subtro-
chanter(ic)’ AND ‘fracture’ AND/OR ‘femur/femoral’
AND/OR ‘atypical’ AND/OR ‘low-trauma’ AND/OR
‘low-energy’. Scientific papers pertinent to subtrochanteric
fractures following bisphosphonate use were analysed and
included in the evidence base.
Characteristics of subtrochanteric fractures
Subtrochanteric fractures have been defined as occurring in
a zone extending from the lesser trochanter to 5 cm distal to
the lesser trochanter [32]. However, this anatomical
classification of subtrochanteric fracture has several varia-
tions [33, 34], resulting in variable definitions in published
studies [26, 30, 35].
Regardless of the definition used, many case reports and
case reviews have suggested that there are several common
features of subtrochanteric fractures associated with
bisphosphonate use. Major features were that the fractures
arose with minimal or no trauma and, on radiography, the
fracture line was transverse. Minor features were that
fractures were commonly preceded by prodromal pain
and, on radiographs, there appeared beaking of the cortex
on one side and bilateral thickened diaphyseal cortices [26,
28, 36–39]. This fracture pattern has often been referred to
as an ‘atypical subtrochanteric fracture’ [40–42] although,
374 Osteoporos Int (2011) 22:373–390as reviewed below, the distinction between typical and
atypical subtrochanteric fractures has not yet been firmly
established.
It is worth noting that, on radiography, the appearance of
atypical subtrochanteric fractures is similar to that of stress
fractures, including a periosteal reaction, linear areas of
bone sclerosis and a transverse fracture line. Prodromal
pain prior to diagnosis is also common [43]. However,
stress fractures are more commonly associated with
repeated episodes of increased activity (e.g. participation
in sports). Nevertheless, stress fractures due to non-
traumatic loading in patients with low bone density do
occur (insufficiency fractures) [43]; thus, the terms ‘atyp-
ical’ and ‘stress’ are often used interchangeably or in
conjunction to describe subtrochanteric fractures in this
context. However, this terminology also requires clarifica-
tion, as not all stress fractures are atypical.
Epidemiology of subtrochanteric fractures
Subtrochanteric fractures are a relatively rare type of hip
fracture [44–46], usually resulting from high-energy trau-
ma, pathologic fracture or, in the elderly, low-energy injury
involving osteoporotic bone. Several series report the
incidence of this fracture [25–28, 30, 36, 37, 47], although
the definition of the subtrochanteric site has varied. Nieves
et al. reported a large, 11-year epidemiological study of
fractures of the hip, subtrochanter, femoral shaft and distal
femur in the US population aged ≥50 years using National
Hospital Discharge Survey data from the National Center
for Health Statistics and MarketScan® (medical claims
experience) data [46]. Of all femoral fractures, 3% were at
the subtrochanteric region, 5% at the femoral shaft, 5% at
the distal femur and 87% were at the proximal femur (i.e.
hip). Importantly, this study classified fractures solely
according to their location in the femur and did not evaluate
the fracture patterns radiographically. Thus, they were not
able to determine the incidence of ‘typical’ vs ‘atypical’
subtrochanteric fractures. In men and in women, the
incidence rate of each type of fracture remained stable over
5 years but increased exponentially with age (Fig. 1). Each
fracture type was more prevalent in women than in men.
Seventy-five percent of all femur fracture cases were in
women. The mean age at fracture was 80 years old, and
those with a subtrochanteric fracture were of a similar age
to those with a hip fracture.
Leung et al. published a retrospective analysis that aimed
to document the incidence of low-trauma subtrochanteric or
femoral diaphyseal fractures in a Hong Kong hospital over
a 5-year period [42]. In all, 88 cases of subtrochanteric
fractures and 66 of diaphyseal fractures were identified,
accounting for 3.9% and 2.9% of all recorded osteoporotic
fractures, respectively.
Thus, although the incidence of subtrochanteric fractures
is much lower than other femoral fractures, they are not rare
and account for about 3% of all femoral fractures in the
elderly. If these estimates were applied to the UK, then
more than 2,000 subtrochanteric fractures are expected to
occur each year [48], and approximately 48,000 are
expected annually worldwide [49].
Subtrochanteric fractures and bisphosphonate exposure
Case reports and case reviews
Twenty-six published case reports and case reviews were
identified that were considered relevant, a similar number
to that identified in a recent review by Giusti et al. [50].
Concern about bisphosphonate use in relation to atypical
subtrochanteric fractures arose from case reports that
described patients with subtrochanteric fractures who had
been exposed to bisphosphonates, particularly long-term
treatment with alendronate (Fosamax®/Fosavance®, alendr-
onate sodium, Merck Sharp & Dohme Limited). The
Fig. 1 Age-specific incidence
of femoral fractures according
to fracture site in men (X) and
women (O) aged ≥50 years
(adapted from Nieves et al. [46])
Osteoporos Int (2011) 22:373–390 375association between long-term bisphosphonate use and
unusual diaphyseal fractures was first described by Odvina
et al. in 2005 [31] who reported nine patients with
osteoporosis or osteopenia who had been treated with
alendronate for 3–8 years and sustained atraumatic
fractures in the course of their normal daily activities.
Three patients had fractures of the femoral shaft and two
had fractures of the proximal femur. Of these five patients,
fracture healing was radiographically assessed in four. All
four patients had delayed or absent fracture healing
ranging from 4 months to 2 years while on alendronate
treatment.
ThisandsubsequentcasereportsaresummarizedinTable1.
The mean and median age of patients was 65 years (range
35–85). All cases involved treatment with alendronate,
except for five patients who took risedronate (Actonel®,
risedronate sodium, Procter and Gamble Pharmaceuticals)
and three who took pamidronate (Aredia®, pamidronate
disodium, Novartis Pharmaceuticals Limited). One patient
had been taking ibandronate (Bonviva®/Boniva®, ibandronic
acid, Roche) for 1 year following long-term alendronate use,
and one had been taking risedronate for 5 years following
7 years of pamidronate use. There were no published case
reports of subtrochanteric fractures following the use of once-
yearly zoledronic acid 5 mg (Aclasta®/Reclast®, zoledronic
acid anhydrous, Novartis Pharmaceuticals Limited), although
cases following treatment with the monthly 4-mg dose have
been reported [36, 38]. The mean and median duration of
bisphosphonate use was 7.3 and 7.5 years, respectively
(range 1–16), and the majority of patients had unilateral
fractures (29 out of 43; 67.4%).
In addition to case reports, several case reviews have
been published, which are summarized in Table 2. For
example, the characteristics of low-trauma subtrochanteric
and diaphyseal fractures were studied retrospectively by
Neviaser et al. in all patients admitted to a US trauma centre
over a 5-year interval (Table 2)[ 30]. Radiographs were
examined by independent experts to identify fractures with
a simple, transverse or short oblique pattern in areas of
cortical hypertrophy with a cortical beak. The observers
were blinded to patient characteristics, including alendro-
nate use. Seventy patients were identified, of whom 25
were treated with alendronate. Nineteen out of 25 (76%)
alendronate-treated patients had the radiographic pattern
compared with one out of 45 (2%) non-alendronate-treated
patients. Thus, the risk of having an ‘atypical’ subtrochan-
teric fracture pattern was significantly associated with
alendronate use (odds ratio=139; 95% confidence interval
(CI) 19–939; p<0.0001). The mean duration of treatment
with alendronate was 6.2 years (6.9 years in those who had
the fracture pattern vs 2.5 years in those who did not) [30].
The authors concluded that there are unique features to
bisphosphonate-associated fractures.
Controlled studies
Six studies that utilized control groups were identified that
have investigated the association of subtrochanteric frac-
tures with the use of bisphosphonates. In the study of
Nieves et al. described above, the rate of subtrochanteric
and femoral shaft fractures appeared to be higher than that
of other fractures in women taking oral bisphosphonates
(Fig. 2)[ 46], although there is no statistical information
provided. It is not known whether excess fractures were due
to trauma or not. The study concluded, however, that there
was no evidence of an increase in the incidence of
subtrochanteric or femoral shaft fracture between 1996
(around the time that bisphosphonates were first intro-
duced) and 2006. Limitations of these data include the lack
of radiological and clinical verification and no information
on the type of bisphosphonate used or the duration of
treatment.
In a study by Leung et al., ten patients with subtrochan-
teric fractures who had received alendronate were identified
over a 5-year period. This included one patient who had
taken alendronate for 1 year followed by ibandronate for
2 years [42]. The crude incidence of subtrochanteric/
femoral diaphyseal fractures associated with prior
bisphosphonate use increased over 5 years from 0% in
2003/2004 to 6% in 2004/2005, 8.6% in 2006/2007 and
25% in 2007/2008. This trend was despite a steady annual
incidence of subtrochanteric/femoral diaphyseal fractures. It
is difficult to draw meaningful conclusions from these data
because of the very small sample size (ten subtrochanteric
fractures in patients exposed to a bisphosphonate) and the
lack of information on bisphosphonate use at other fracture
sites. At best, the study documents the increasing use of
bisphosphonates over the time of study.
In a small retrospective case–control study, Lenart et al.
a i m e dt oi d e n t i f ya na s s o c i a t i o nb e t w e e nl o w - e n e r g y
subtrochanteric/femoral shaft fractures (according to the
Müller AO classification) and long-term bisphosphonate
use [29]. Forty-one low-energy subtrochanteric or femoral
shaft fracture cases were identified and matched by age,
body mass index and race to one low-energy intertrochan-
teric and femoral neck fracture each.
Fifteen out of the 41 (37%) cases of subtrochanteric or
femoral shaft fracture cases were taking bisphosphonates,
compared with nine out of 82 (11%) controls (OR=4.4;
95% CI 1.8–11.4; p=0.002). Alendronate was the
bisphosphonate taken in all cases. Eight out of nine cases
in the control group were taking alendronate (one had
previously taken etidronate). A radiographic pattern of a
simple transverse or oblique fracture, beaking of the cortex
on one side and cortical thickening at the fracture site, was
observed in ten of the 15 (67%) subtrochanteric/femoral
shaft fracture cases taking bisphosphonate and three of the
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Osteoporos Int (2011) 22:373–390 37926 (11%) subtrochanteric/femoral shaft fracture cases not
taking bisphosphonate (OR=15.3; 95% CI=3.1–76.9;
p<0.001). The duration of bisphosphonate exposure was
significantly longer in patients with this X-ray pattern [29].
K o he ta l .c a r r i e do u tar e t r ospective clinical and
radiological review of geriatric hip fracture patients at a
Singapore tertiary centre over 4 years to assess features that
predispose to complete stress fractures [38]. Thirty-two
patients with spontaneous or low-energy fractures with
metaphyseal–diaphyseal involvement and on bisphospho-
nate therapy were identified. All were on alendronate
therapy except for one who was on monthly zoledronic
acid 4 mg and one who had been on risedronate for 6 years
following 4 years of alendronate. Of these, 16 patients
(median duration of therapy 4.5 years) had radiographic
evidence of lateral cortical thickening. Four had cortical
stress lesions on the prefracture radiograph (group F) and
12 had cortical stress lesions on the contralateral femur
(group C). The type of bisphosphonate taken by patients
according to group was not detailed. All patients in group F
experienced prodromal thigh discomfort, compared with
25% of patients in group C (p=0.019), and radiographic
evidence of a stress line across the cortical thickening
occurred in 100% and 8% of patients, respectively
(p=0.003). At a median follow-up of 23 months, none of
the patients in group C had developed a complete fracture.
All of these patients except for one had discontinued
bisphosphonate therapy; five had not taken any alternative
therapy since discontinuation. Nevertheless, eight out of the
11 were asymptomatic, and no new cortical thickening was
detected in any of the patients. The authors concluded that,
in people taking long-term bisphosphonate therapy, symp-
tomatic cortical stress reactions accompanied by evidence
of a stress line across the cortical thickening suggest an
increased risk of a complete stress fracture [38].
In the only population-based study that included radio-
logical review of all cases, Schilcher and Aspenberg
studied the incidence of stress fractures at the femoral shaft
in bisphosphonate-treated patients in four hospitals in
Sweden. Women aged over 55 years with fractures of the
femoral diaphysis or subtrochanteric region were identified
from the operation registry. Preoperative radiographs were
examined to identify stress fractures, defined as a transverse
fracture of the femoral shaft with cortical thickening. Of
91,956 women identified, 3,087 bisphosphonate users were
identified, of whom five had femoral stress fractures. All of
these five patients were aged >75 years, and their mean
duration of treatment was 5.8 years [66]. Three patients that
were not treated with bisphosphonates had stress fractures.
All were aged <75 years. The annual incidence of femoral
shaft stress fractures in bisphosphonate users was 1/1,000
per year (95% CI 0.3–2) vs 0.02/1,000 (0.004–0.1) per year
in control patients. Thus, the risk of such fractures was
estimated to be 46 times greater with bisphosphonate use
(95% CI 11–200) [65]. An obvious weakness of the study is
that, although the confidence intervals were corrected for
sample size, the findings were based on just eight femoral
shaft stress fractures. The results thus raise a hypothesis to
be tested on larger samples.
A larger study is provided by Abrahamsen et al. who
studied the epidemiology of subtrochanteric and diaphyseal
femur fractures in patients in Denmark treated with
alendronate [67]. However, in contrast to the Schilcher
and Aspenberg report, in this study, radiographic fracture
patterns were not reviewed, and thus, fractures were
identified purely based on their location. In patients aged
≥60 years that had subtrochanteric, diaphyseal femur and
hip fractures in 2005, the incidence of subtrochanteric (n=
898) and diaphyseal fractures (n=720) were similar, and the
ratio of high-to-low-energy trauma fractures was the same
for each of these fracture types (approximately 2.5:1 for
each). Exposure to alendronate was also similar between
fracture types (approximately 7% each). Patients with
subtrochanteric fractures and diaphyseal fractures were
more likely to have taken glucocorticoids in the year before
fracture than patients with hip fracture (10.9%, 8.4% and
6.5% of patients, respectively).
In a register-based matched cohort analysis, Abrahamsen
et al. investigated whether the increase in risk of ‘atypical’
femur fracture in alendronate-treated patients was greater
than the increase in risk of ‘typical’ osteoporotic femur
fractures (‘typical’ and ‘atypical’ were not defined). In total,
15,187 patients who took alendronate for ≥6 months after
the fracture event (the treatment cohort) were compared
with two randomly assigned sex-, age- and fracture-
matched controls (n=10,374). The use of alendronate was
associated with an increase in the hazard ratio (HR;
adjusted for baseline comorbidities) for both subtrochan-
teric/diaphyseal fractures (HR=1.46; 95% CI 0.91–2.35;
p=0.12) and hip fracture (HR=1.45; 95% CI 1.21–1.74;
p<0.001). Subtrochanteric/diaphyseal fractures were equal-
ly common in the alendronate-treated (14% of hip fractures)
and control patients (13%; p=0.70). Both hip fractures and
subtrochanteric/diaphyseal fractures were significantly low-
er in patients with higher adherence (HR=0.47 [0.34–0.65;
p<0.001] and 0.28 [0.12–0.63; p<0.01], respectively). In a
sub-analysis of 178 compliant (medication possession
ratio >80%) patients who took alendronate for >6 years,
long-term alendronate use was associated with no change in
both hip (HR=1.24 [0.66–2.34]; p=0.52) and subtrochan-
teric/diaphyseal fractures (HR=1.37 [0.22–8.62]; p=0.74).
The incidence of subtrochanteric/diaphyseal fractures was
similar in the long-term alendronate (10%) and control
(12.5%) groups (10% vs 12.5%, respectively) [67].
This study, in a large number of patients, does not
support the hypothesis that exposure to alendronate is
380 Osteoporos Int (2011) 22:373–390T
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382 Osteoporos Int (2011) 22:373–390associated with an increased frequency of subtrochan-
teric fractures compared with controls. However, the
same study reported that treatment with alendronate was
associated with an increased risk of hip fracture. This
should not be interpreted as ‘alendronate causes hip
fracture’, but only that high-risk patients are exposed to
alendronate. The finding also illustrates the difficulties
in the interpretation of retrospective observational
studies, particularly accounting for selection bias that
likely confounds the other much smaller observational
studies.
Randomized controlled trials
Black et al. recently reported an analysis of subtrochanteric
and diaphyseal fractures in the Fracture Intervention Trial
(FIT) of alendronate and its extension [1, 2, 5, 68] and the
HORIZON Pivotal Fracture Trial (PFT) of zoledronic acid
5m g[ 3]. Twelve fractures in ten patients were documented
in the subtrochanteric or diaphyseal region (Table 3)a
combined rate of 2.3 per 10,000 patient-years [69].
However, radiographs were not available to confirm typical
vs atypical radiographic features. There was no significant
increase over placebo in the risk of subtrochanteric/
diaphyseal fractures during the FIT, FIT Long-Term
Extension (FLEX) or HORIZON-PFT trials. Compared
with placebo, the relative hazard was 1.03 (95% CI 0.1–
16.5) for alendronate use in the FIT trial, 1.5 (95% CI 0.3–
9.0) for zoledronic acid in the HORIZON-PFT and 1.3
(95% CI 0.1–14.7) for continued alendronate use in the
FLEX trial. The interpretation of this analysis is limited by
the small number of events and the large confidence intervals.
Bilezikian et al. reported the incidence of subtrochanteric
fractures in the randomized, placebo-controlled phase III
studies of risedronate in post-menopausal osteoporosis,
which enrolled more than 15,000 patients. In trials of up
to 3 years duration, the mean incidence of subtrochanteric
fractures was 0.14% in risedronate 2.5-mg treated patients
(n=4,998), 0.13% in risedronate 5-mg treated patients (n=
5,395) and 0.17% in placebo-treated patients (n=5,363)
[70]. In active control studies of risedronate involving
various doses (35 mg once weekly, 75 mg on two
consecutive days per month, 150 mg once monthly), no
subtrochanteric fractures were reported, and the incidence
of hip/femoral fractures was similar to that in the placebo-
controlled studies [70].
The manufacturers of ibandronate have assessed their
clinical trials database to determine the incidence of
subtrochanteric and diaphyseal femoral fractures in women
taking ibandronate for post-menopausal osteoporosis. Atyp-
ical fractures were defined as ‘mostly non-spine fractures
including hip or femur fractures in the subtrochanteric
region or shaft and occurring without trauma or in
association with low-energy trauma’. For femur fractures,
subtrochanteric fracture location was considered as atypical
for osteoporosis-related fractures, defined as a region below
the lesser trochanter and a junction between the proximal
and middle third of the femoral shaft. In the pivotal trials
(MF 4380, BONE, MOBILE and DIVA) [4, 71–73], there
were nine fracture cases corresponding to these defined
locations and characteristics (subtrochanteric, femoral shaft,
stress or multiple fractures): six occurred in placebo-treated
patients (n=1,924) and three in ibandronate-treated patients
(n=6,830). In addition, there was one identified case of a
0 5 10 15 20 25 30 35 40
Oral glucocorticoids
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Proton pump inhibitors
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Estrogens
Raloxifene
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Fig. 2 Medical and prescription
drug history in US female frac-
ture patients (2002–2006) dur-
ing the 1 year before index date
(adapted from Nieves et al. [46])
Osteoporos Int (2011) 22:373–390 383femoral shaft fracture in an ibandronate-treated patient in
the extension and major phase IIIb trials (MOBILE LTE,
DIVA LTE, MOTION and PREVENTION; n=2,451) [74–
77]. Some fractures were reported without identifying the
precise location. However, all of these fractures were
associated with trauma and thus did not meet the definition
for atypical fractures. An additional 5-year analysis of the
marketed regimens of ibandronate (150 mg once monthly
and 3 mg IV quarterly) was also carried out from the active
comparator-controlled trials and their extensions (MOBILE,
DIVA, MOTION, MOBILE LTE and DIVA LTE) [71, 72,
74, 75, 77]. No atypical subtrochanteric/diaphyseal femoral
fractures were found for either of the marketed regimens
(150 mg, n=1,279; 3 mg, n=469).
Pharmacovigilance data
Since fractures are the clinical outcome of osteoporosis
and no treatments are fully effective, fractures are
expected in treated patients. It is likely, however, that
the number of reports through pharmacovigilance will be
small. The number of postmarketing reports of atypical
stress fractures in association with alendronate to circa
July 2008 was 115 (of which 84 were femur fractures)
and included a large number of the cases reported in the
literature [78].
Bilezikian et al. have reported that in more than 10 years
of risedronate post-approval surveillance to September
2008 (18 million patient-years of exposure), the reporting
rate for subtrochanteric fractures was <0.1 per 100,000
patient treatment years of exposure [70].
Postmarketing data from the manufacturers of zoledronic
acid have revealed a similarly low rate of subtrochanteric
fractures with zoledronic acid 5 mg. Using the last cutoff
date for worldwide Health Authority Reporting prior to
January 2010 (Periodic Safety Update Report v6) and
assessing all adverse event reports for zoledronic acid 5 mg
(579,501 patient-years of exposure), the rate of femoral
subtrochanteric fracture reporting was three per 1,000,000
patient treatment years of exposure.
Postmarketing data from the manufacturers of ibandro-
nate have also revealed a low rate of possible atypical
fractures occurring in patients receiving ibandronate for the
management of postmenopausal osteoporosis. According to
their global safety database as of June 2009, cumulative
postmarketing exposure of ibandronate yielded a crude
reporting rate of possible atypical fractures of approxi-
mately one per 1,000,000 patients. Three of the cases
involved alendronate treatment followed by ibandronate
treatment and were reported in the case series of Ing-
Lorenzini et al. [27].
Regulatory perspective
In July 2008, the Pharmacovigilance Working Party
(PhVWP) of the Committee for Medicinal Products for
Table 3 Characteristics of ten patients with 12 low-trauma subtrochanteric or femoral diaphyseal fractures in the FIT, FLEX and HORIZON-PFT
trials (adapted from Black et al. [69])
Study Age
(years)
Study
medication
Time from
randomization
to fracture
(days [years])
Bilateral? Prodromal
symptoms
Compliance Concomitant therapy
FIT 75 Placebo 962 (2.6) >75% None
FIT 69 Alendronate 1,682 (4.6) >75% None
FLEX 79 Alendronate
(first fracture)
1,250 (3.4) Stopped 3 years
before first fracture
Alendronate, 6 years (in FIT
before FLEX)
Alendronate
(second fracture)
1,369 (3.8)
FLEX 80 Alendronate/
placebo
1,257 (3.4) Stopped 3 years
before fracture
Alendronate, 6 years (in FIT
before FLEX)
FLEX 83 Alendronate/
alendronate
1,006 (2.8) >75% Alendronate, 5 years (in FIT
before FLEX)
HORIZON 65 Zoledronic acid 454 (1.2) Hip pain 100% Raloxifene
HORIZON 78 Placebo 1,051 (2.9) Hip pain 100% None
HORIZON 65 Zoledronic acid 732 (2.0) 100% None
HORIZON 72 Placebo 321 (0.9) 100% Calcitonin
HORIZON 71 Zoledronic acid
(2 fractures)
934 (2.6) Yes Bone pain 100% Bisphosphonate and hormone
replacement therapy, both
before study
384 Osteoporos Int (2011) 22:373–390Human Use (CHMP) initiated a class review on bisphosph-
onates and atypical stress fractures. Marketing Authoriza-
tion Holders supplied information about all preclinical,
clinical and future studies, published case reports, post-
marketing data, possible mechanisms and proposed risk-
minimization activities. Following a PhVWP review of
these data in December 2008, the CHMP concluded that
there was an association between atypical stress fractures
and long-term use of alendronate, due to the distinct
fracture pattern, prodromal pain and poor fracture healing.
However, the benefit–risk balance of alendronate use was
considered favourable. The CHMP highlighted that there
was uncertainty concerning a class effect for other
bisphosphonates and that switching of bisphosphonates
should be avoided at this time. Ultimately, the CHMP
recommended that information about atypical stress
fractures should be added to the product information
for medicinal products containing alendronate [78].
Consequently, the labelling for alendronate (Fosamax®/
Fosavance®, Merck Sharp & Dohme Limited) now
includes a special warning/precaution for alendronate use,
advising discontinuation of bisphosphonate therapy in
patients with stress fracture pending evaluation, based on
an individual benefit–risk assessment [22, 79]. Alendronate
is the only bisphosphonate for osteoporosis treatment that
currently carries this warning.
In addition to the 2008 class review, the EMEA
released a statement in August 2009 highlighting their
2010 priorities for drug safety research with regards to
the long-term adverse skeletal effects of bisphospho-
nates: (1) generate methodologies to study the link
between bisphosphonate use and long-term adverse
skeletal events in human populations and (2) measure
the incidence of stress/insufficiency fractures in associ-
ation with high-dose/long-term use of bisphosphonates
by class, compound, mode of administration, dose etc.
Methods could include meta-analysis or nested case–
control studies [80].
In June 2008, the US Food and Drug Administration
(FDA) initiated a review of bisphosphonates for a
possible association with increased risk of atypical
subtrochanteric femur fractures. All available case reports
and clinical trial data were requested from all bisphosph-
onate drug manufacturers andw e r er e v i e w e da l o n g s i d e
the registry data from the large observational study of
Abrahamsen et al. [67]. In March 2010, the FDA
announced that the data reviewed had not shown a clear
connection between bisphosphonate use and the risk of
atypical subtrochanteric fractures. Physicians were urged
to continue to follow the labelling when prescribing
bisphosphonates and patients were instructed not to
discontinue their medication unless instructed to do so
by their physician [81].
Pathophysiology of subtrochanteric fractures associated
with bisphosphonate use
The pathophysiology of atypical low-trauma subtrochan-
teric fractures following bisphosphonate use is not known.
However, preclinical and clinical studies of the effects of
bisphosphonates on bone suggest that there are several
possible mechanisms that work either alone or in tandem.
The organic matrix of the bone determines its toughness,
and this matrix is partly made up of bone collagen, which
impacts on the bone’s mechanical properties. Bisphospho-
nate use may negatively affect collagen by preventing or
reducing its maturation [82], although this finding has not
been consistently replicated [83]. Bisphosphonates may
also affect bone mineralization density distribution
(BMDD). The more heterogeneous the BMDD, the slower
that cracks in the bone will develop and the lower the risk
of new cracks and fractures forming [84]. As bisphospho-
nate treatment reduces bone turnover, the increase in overall
mineralization leads to more homogeneous bone—as
evidenced by a narrow BMDD [85, 86]—and thus an
increased risk of cracks and fractures. Reduced bone
turnover also increases the accumulation of microdamage,
as cracks are not repaired [87], and reduces bone toughness,
which contributes to the increased susceptibility of bone to
new cracks [88–90]. Finally, bisphosphonates have differ-
ing impacts on different types of fracture. Acute fractures of
long bone are not affected by bisphosphonates in the initial
healing stages [91–93], as they heal via endochondral
ossification. However, stress fractures heal by normal bone
remodelling, and thus, bisphosphonates may prevent or
delay healing, increasing the likelihood of a complete
fracture with little or no trauma. Several reports have
reported on bone quality in people with low-trauma
fractures taking bisphosphonate therapy.
For example, Odvina et al. reported that cancellous bone
histomorphometry in alendronate-treated patients (3–
8 years) who sustained spontaneous non-vertebral fractures
showed markedly suppressed bone formation, with reduced
or absent osteoblastic surface in most patients. Osteoclastic
surface was also low in most patients, and eroded surface
decreased in half [31]. Odvina et al. reported similar
findings in a later report in a comparable patient population
[58]. In a case report by Armamento-Villareal et al. of a
man who had a low-trauma subtrochanteric fracture after
discontinuing 6 years of alendronate treatment, a bone
biopsy showed severely decreased trabecular connectivity, a
lack of osteoid on trabecular surfaces and an absence of
tetracycline labelling [53]. Armamento-Villareal et al. later
reported that of 15 bisphosphonate-treated patients (2–
10 years; Table 2) who underwent bone biopsies following
a low-energy cortical (femoral shaft, pelvis, rib, metatarsal,
ankle) fracture, ten had an absence of double-tetracycline
Osteoporos Int (2011) 22:373–390 385label, reduced osteoid surface and thickness suggestive of
suppressed trabecular bone remodelling. However, there
was no difference in cortical thickness between patients
with suppressed (n=10) and normal (n=5) turnover [25].
Recent findings by Somford et al., however, suggest an
alternative pathophysiology for subtrochanteric fractures
associated with bisphosphonate treatment. In a patient who
was treated with alendronate for 8 years and subsequently
developed spontaneous bilateral subtrochanteric/diaphyseal
fractures, biopsies showed a marked decrease in bone
formation as expected; however, this was not coupled with
the expected decrease in bone resorption. In fact, bone
resorption parameters such as osteoclast number were
markedly increased in the femur sample. In addition,
there was no evidence of hypermineralized bone. This
suggests that an imbalance between bone resorption and
bone formation at the affected femur—the cause of
which is currently unknown—rather than excessive
suppression of bone turnover may be the underlying
mechanism for subtrochanteric/diaphyseal femoral frac-
tures in bisphosphonate-treated patients [94].
Summary of evidence
The view that bisphosphonates increase the risk of
subtrochanteric femoral fractures arises from the case
reports and retrospective case reviews that have reported
‘atypical’ subtrochanteric and diaphyseal fractures in
patients exposed to bisphosphonates. In all, these data
highlight the scope of the problem, i.e. a trend that
warrants further investigation. However, the data in their
entirety are insufficient proof that long-term bisphospho-
nate use is the only cause of atypical low-trauma sub-
trochanteric fractures.
There are several limitations to the existing evidence
base: lack of a consensus definition of an atypical
subtrochanteric fracture, small numbers of patients in-
volved, lack of radiographs which precludes characteriza-
tion of the radiographic features of the fractures and
incomplete reporting of subject characteristics. In addition,
subtrochanteric fractures in general are not atypical frac-
tures; rather, they are part of the natural history of fragility
fractures in osteoporosis. They increase in frequency with
age in much the same way as does the incidence of other
osteoporotic fractures [95]. Although their incidence is
much lower than other femoral fractures, they are not rare
and account for approximately 3% of all femoral fractures
[46]. Thus, the term ‘atypical’ is not synonymous with
‘unexpected’ which is the common interpretation. Rather,
the term should be reserved for subtrochanteric fractures
that have atypical features, of which some are similar to
with those associated with stress.
Therein lies an additional problem in that it has been
difficult to provide characteristics of the fracture that are
associated with the use of bisphosphonates. Candidate
features, which include the prodromal manifestation of
incomplete (fissure) fractures, a thickened cortex and a
transverse fracture pattern with cortical beaking may be
associatedwith the use ofbisphosphonates but,in the absence
of blinded evaluation in all cases, may be subject to large
observer biases. In addition, in many instances, cases have
been complicated, for example, by concomitant exposure to
glucocorticoids [25–28, 31, 39, 50, 55, 58, 63, 65], which
appears to be a risk factor for subtrochanteric fractures [46].
In terms of evidence-based medicine, the ultimate arbiter
for a causal relationship between subtrochanteric fractures
and exposure to bisphosphonates might be expected to
derive from information from RCTs. All the information
available fail to show an association of this fracture with
exposure to bisphosphonates, although all RCTs were
completed before attention was drawn to the problem, so
the documentation of the sites of fracture and any
associated features is inevitably incomplete. Furthermore,
the frequency of the event is sufficiently low that even large
RCTs are insufficiently powered to identify meaningful
associations with drug exposure. Finally, the duration of
exposure to bisphosphonates may be too short in the setting
of RCTs if, as has been suggested, the complication were to
increase in frequency with exposure time. Against this
background, data from observational studies might be
expected to contribute to our understanding, but such
studies are fraught with biases and limitations for which it
may be difficult to adjust.
Research agenda
The ultimate question for physicians is what type of patient
is at the highest risk of an atypical low-trauma subtrochan-
teric fracture. Thus far, apart from long-term alendronate
therapy, suggested risk factors include glucocorticoid,
proton-pump inhibitor or calcitonin use and female gender
[26, 46, 67]. Thus, a number of urgent issues and areas for
research have been identified as follows:
1. Standardized definition of ‘subtrochanteric fracture’,
including a definition of ‘atypical’ and ‘typical’
fractures
2. Provision of descriptive epidemiology based on large-
scale studies with characterization of radiographic
features
3. Definition of fracture incidence by femoral location,
mechanism of injury and underlying pathology
4. Identification of risk factors, with greater clarity as to the
precise risk factors in patients taking bisphosphonates
386 Osteoporos Int (2011) 22:373–3905. Pathophysiological studies in relation to risk factors
6. Pathophysiological studies at the tissue level, i.e. is the
mechanism of atraumatic (insufficiency) fractures dif-
ferent to that of low-trauma fractures?
7. Long-term, large, prospective, observational studies
to assess incidence of subtrochanteric fractures in
bisphosphonate-treated vsbisphosphonate-naïve patients.
Methods should include (1) futility analysis and (2)
radiographic measurements. Outcomes should include
(1) adherence, (2) number needed to harm and (3)
assessment of temporal relationship between bisphosph-
onate treatment and fracture type
8. Long-term, large, prospective, observational studies
allowing for systematic follow-up of patients with
subtrochanteric fractures treated long-term with
bisphosphonates, in order to assess fracture healing
characteristics (e.g. time to healing, choice of
fracture treatment device, adjuvant bone anabolic
intervention etc.)
9. Large, prospective, randomized, controlled clinical
trials of the efficacy and safety of pharmacological
treatment (e.g. strontium ranelate, teriparatide) for
patients with subtrochanteric fractures
Conclusions and recommendations
A sense of proportion may be helpful in alleviating the
concerns of the medical community. A plausible scenario is
that long-term exposure to bisphosphonates (more than
5 years) increases the risk of subtrochanteric femoral
fractures twofold. In the UK, using the guidance of the
National Osteoporosis Guideline Group, the relative risk of
hip fracture is expected to be approximately threefold
increased in postmenopausal women identified for treat-
ment [96]. Assuming that the average population risk of
hip fracture is 1% per year in postmenopausal women,
then 300 hip fractures are expected for every 10,000
patients identified to be at high risk. If these patients
were treated and assuming an effectiveness of bisphosph-
onates of 36% (RR=0.64) [97], then 108 hip fractures are
averted by treatment (and approximately 750 fractures at
other sites). On the debit side, three subtrochanteric
fractures (both typical and atypical) are to be expected,
which might increase to six if bisphosphonates doubled
the risk of all subtrochanteric fractures. Under the assump-
tions of this scenario, the risk–benefit ratio remains very
favourable.
Evidence, including that from an EMEA class review,
suggests that alendronate use may potentially increase the
risk for atypical, low-trauma subtrochanteric fractures,
although it is unclear whether this applies to other
bisphosphonates. Irrespective of exposure to bisphospho-
nates, the occurrence of subtrochanteric fractures is an
expected finding in patients with osteoporosis. If atypical
fractures do occur, then their characteristics are poorly
defined, their causality with bisphosphonate exposure
insecure and their frequency rare. Bisphosphonates as the
cause of atypical fractures at the subtrochanteric site is
therefore still merely a hypothesis, though no less important
for that. Clearly more research is required from well-
designed prospective observational studies, meta-analyses
and nested case–control studies.
Thus, the available evidence does not suggest that the
well-known benefits of bisphosphonate treatment are out-
weighed by the risk of these rare, atypical, low-trauma
subtrochanteric fractures. Nevertheless, it is recommended
that physicians remain vigilant in assessing their patients
treated with bisphosphonates for osteoporosis or associated
conditions. They should continue to follow the recommen-
dations on the drug label when prescribing bisphosphonates
and advise patients of the potential risks. Patients with pain
in the hips, thighs or femur should be radiologically
assessed and, where a stress fracture is evident, the
physician should decide whether bisphosphonate therapy
should be discontinued pending a full evaluation, based on
an individual benefit–risk assessment. The radiographic
changes should be evaluated for orthopaedic intervention—
since surgery prior to fracture completion might be
advantageous—or be closely monitored.
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